Navigation Links
Questcor to Report Second Quarter Financial Results on July 30, 2013
Date:7/12/2013

ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July  30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments..

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 16591264.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
2. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
3. Questcor Adds Angus C. Russell to Board of Directors
4. Questcor Reports First Quarter Financial Results
5. Questcor to Report First Quarter Results on April 30, 2013
6. Questcor Reports Fourth Quarter and Full Year 2012 Results
7. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
8. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
11. Questcor to Conduct Conference Call to Discuss Reimbursement Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced further details ... behavioral and functional aspects of Lewy body dementia, ... the U.S. Two out of the three studies ... to start later this quarter. In addition, the ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment ... reveals that global diagnostic ultrasound devices market was valued at US$ ... million by 2019 at a CAGR of 6.8% from 2015 to ... has been analyzed for six geographies of North America ... , Latin America , Middle-East ...
(Date:2/9/2016)... 9, 2016 The new report "Global Blood Monitoring & Cardiac Monitoring ... & Consulting group reveals that global market for blood monitoring & ... and expected to grow to US$ 24,830.1 million by 2019 at ... North America , Europe , ... Middle-East and Africa . The three ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Transformation Solutions, LLC to help enterprises move workloads to the cloud. Cirracore ... connect to their cloud without traversing the Internet. Transformation Solutions (TSL Partners) ...
(Date:2/9/2016)... ... , ... Establishment Labs, a global breast implant and medical technology company, is ... Directors. , “We are honored to welcome David to our Board of ... Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, ... Younkers department stores, announced it has raised $176,000 to benefit the Breast Cancer ... Cancer Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, ...
(Date:2/9/2016)... ... ... METTLER TOLEDO has published a new guide entitled “Essential ... the techniques they use so they can more easily spot potential error sources ... to create a leaner overall lab experience. , The new guide offers ...
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications ... of Prevention,” an animated video designed to prevent the next widespread ... the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire ...
Breaking Medicine News(10 mins):